Accessibility Menu
Klotho Neurosciences logo

Klotho Neurosciences(NASDAQ) KLTOW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)+14%
5 YearN/A
1 Year-0%
1 Month+7%
N/A
Klotho Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 0.162026-08-31
Klotho Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+33.08%USD 0.122026-08-24
1 month+7.04%USD 0.152026-07-31
3 month-35.99%USD 0.252026-06-02
Year to date+66.53%USD 0.102025-12-31
1 year-0.44%USD 0.162025-08-29
3 year+141.79%USD 0.072023-08-31
Since inception+14.07%USD 0.142022-04-29

Klotho Neurosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.77M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

KLTOW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Klotho Neurosciences

Klotho Neurosciences, Inc. is a biopharmaceutical company dedicated to developing innovative medical treatments for severe illnesses, including cancer, heart disease, and neurological disorders. The company is advancing gene therapy candidates aimed at addressing Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Products and Services
  • Gene therapy candidate AMI-101 for Alzheimer's disease
  • Gene therapy candidate AMI-202 for ALS management
  • Research and development focused on severe illnesses
Growth Outlook
  • Significant market potential in neurodegenerative diseases
  • Strong pipeline with multiple gene therapy candidates
  • Increased investment in R&D to drive innovation
Financial Highlights
  • Recent quarterly net income of -$13.86 million
  • Cash and cash equivalents of $10 million as of March 2026
  • Current ratio of 19.74 indicates strong liquidity position
Klotho Neurosciences, Inc. is positioned in a rapidly evolving biotechnology sector, focusing on critical health challenges. The company's commitment to research and development is evident in its innovative gene therapy candidates, which target significant unmet medical needs. The financial data reflects a robust liquidity position, with substantial cash reserves to support ongoing research initiatives. Despite recent net losses, the strong current ratio suggests that the company can meet its short-term obligations while continuing to invest in its growth strategy. The potential for market expansion in neurodegenerative diseases presents an attractive opportunity for future development and investor interest.
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Omaha, NE 68144, US

KLTOW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-67.62%

Return on Capital

-75.51%

Return on Assets

-33.48%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$18.67M

EBITDA

-$23.01M

Operating Cash Flow

-$13.90M

Capital Expenditure

-$682.85K

Free Cash Flow

-$14.58M

Cash & ST Invst.

$9.34M

Total Debt

$297.97K

Klotho Neurosciences Performance Analysis

Klotho Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Klotho Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3059.5%
Q42025-12-3162.6%
Q12026-03-31-724.2%
Q22026-06-3080.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

3

N/A

Net Income

-$3.69M

+10.0%

EBITDA

-$5.49M

-190.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$9.34M

+10.8%

Total Debt

$297.97K

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$297.97K

N/A

Return on Assets

-33.48%

N/A

Return on Invested Capital

-29.26%

N/A

Free Cash Flow

-$6.88M

-249.4%

Operating Cash Flow

-$6.56M

-233.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALECAlector, Inc.
$2.26-3.42%
BDTXBlack Diamond Therapeutics, Inc.
$2.10-5.83%
CARMCarisma Therapeutics, Inc.
$0.00+0.00%
DAICCID HoldCo, Inc.
$3.48-25.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About KLTOW

What is the current price of Klotho Neurosciences?

Klotho Neurosciences is trading at N/A per share.

What is the 52-week range for Klotho Neurosciences?

Over the past 52 weeks, Klotho Neurosciences has traded between N/A and N/A.

How much debt does Klotho Neurosciences have?

Klotho Neurosciences total debt is unavailable.

How much cash does Klotho Neurosciences have on hand?

Klotho Neurosciences does not have cash on hand data available.

What is Klotho Neurosciences’s dividend yield?

Klotho Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services